福元醫藥(601089.SH):鹽酸溴己新口服溶液獲得藥品註冊證書
格隆匯6月6日丨福元醫藥(601089.SH)公佈,公司全資子公司福元藥業有限公司(稱“福元藥業”)收到了國家藥品監督管理局頒發的鹽酸溴己新口服溶液(規格1:40ml:80mg;規格2:100ml:0.2g,簡稱“該藥品”)《藥品註冊證書》(證書編號:規格1:2025S01639;規格2:2025S01640)。
本品適用於成人、青少年和6歲及以上兒童的粘液分泌或粘液清除障礙相關呼吸系統疾病的對症治療:急性支氣管炎、氣管支氣管炎、慢性支氣管炎;慢性阻塞性支氣管肺部疾病、支氣管擴張症;急性鼻竇炎、慢性鼻竇炎。
該藥品獲得《藥品註冊證書》,將進一步豐富公司產品線,有助於提升公司產品的市場競爭力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.